Someone stated "most Covid patients improve anyway" or something to that effect. That is true. And it is probably also true that in such a small trial, seeing the distinction between Brilacidin and the SOC may be more difficult. But beyond simply the question of OVERALL improvement, we can also have RATE of improvement differences. THAT might be the difference. As to Mo's point about the CRO "knowing", I don't think so. The double blinding is designed to prevent that FOR EVERYONE. It seems that the CRO would have to be actively reviewing all results to see such distinctions and I believe their job is simply to insure trial integrity, not analyze results. JMO. In any event, it won't be long now before results are available. I've added some to my large stash recently because I see good things on the horizon. But that's just me.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links